Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, Stephen L. Hauser, David Li et al.|The Lancet|2011Cited by 743
Ofatumumab versus Teriflunomide in Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2020Cited by 706
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complexJ. L. Haines, Jorge R. Oksenberg, Robin Lincoln et al.|Nature Genetics|1996Cited by 654